Sanofi
As of the edition of 20 October 2026, Sanofi runs 402 drugs, 207 of them marketed; it is on route A at 53 targets and on route B at 55 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
Sanofi was renamed in 2011.
The records place 29 company names in this family.
- Aventis Behring GmbH: acquired in 2004; successor Sanofi
- Aventis Pharmaceuticals: acquired in 2004; successor Sanofi
- Chattem, Inc.: acquired in 2010; successor Sanofi
- Sanofi: renamed in 2011
- Translate Bio, Inc.: acquired in 2021; successor Sanofi
- Kadmon Corporation, LLC: acquired in 2021; successor Sanofi
- Sanofi Belgium: acquired in 2023; successor Sanofi
- Provention Bio, Inc.: acquired in 2023; successor Sanofi
- Sanofi B.V.: acquired in 2023; successor Sanofi
- Blueprint Medicines Corporation: acquired in 2025; successor Sanofi
- Vigil Neuroscience, Inc.: acquired in 2025; successor Sanofi
Drugs by status
| Status | Count |
|---|---|
| Marketed | 207 |
| Active | 38 |
| Went quiet | 72 |
| Stopped | 68 |
| Withdrawn from market | 3 |
| Status not established | 14 |
| Total | 402 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Docetaxel anhydrous | none listed | 0 |
| Metformin | none listed | 4 |
| Oxaliplatin | none listed | 0 |
| Fludarabine | none listed | 2 |
| Bupivacaine | none listed | 1 |
| Lidocaine | none listed | 2 |
| Acetaminophen | none listed | 17 |
| Aspirin | none listed | 8 |
| Rosuvastatin | none listed | 3 |
| Ergocalciferol | none listed | 1 |
| Insulin human | Ended 1994 (computed from the first US licence) | 1 |
| Nicotine | none listed | 1 |
| Fludarabine phosphate | none listed | 1 |
| Clopidogrel | none listed | 1 |
| Hydroxychloroquine | none listed | 0 |
| Aflibercept | Ends 2030 (orphan exclusivity) | 4 |
| Rifampin | none listed | 0 |
| Insulin glargine | Ended 2012 (computed from the first US licence) | 0 |
| Sargramostim | Ended 2025 (orphan exclusivity) | 2 |
| Insulin aspart | Ended 2012 (computed from the first US licence) | 0 |
| Alemtuzumab | Ended 2013 (computed from the first US licence) | 1 |
| Ezetimibe | none listed | 3 |
| Valproic acid | none listed | 2 |
| Hydrochlorothiazide | none listed | 4 |
| Metronidazole | none listed | 0 |
A route B row is one company at one target. 182 more marketed drugs are not listed here.
Where it needs a new molecule
Route A at 53 targets, route B at 55 targets.
All 108 rows on route A or B
In the product108 company-target rows on route A or B; 105 are not shown here, and no score is.
See all 108 targets where Sanofi needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 312 trials led
- Immune system: 271 trials led
- Nutrition and metabolism: 257 trials led